Skip to main content
SpringerLink
Log in

L’abatacept dans la polyarthrite rhumatoïde

  • Chapter
Biothèrapies en rhumatologie

  • 255 Accesses

Résumé

Le CTLA4 a été découvert lors de la purification de molécules exprimées par les lymphocytes T (LT) activés. C’est en décidant de détailler les mécanismes de costimulation que le CTLA4-Ig a été produit, alors que les recherches dans ce champ d’investigation avancaient peu par manque d’outils, et notamment d’anticorps spécifi ques. C’est une fois encore à partir des travaux dans les modèles expérimentaux murins, dans le domaine de la transplantation et des maladies auto-immunes, que l’abatacept (CTLA4-Ig) a été développé en misant sur un mécanisme d’action alors novateur, car relatif à la co-stimulation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Abrams JR, Lebwohl MG, Guzzo CA et al. (1999) CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243–52

    Article  PubMed  CAS  Google Scholar 

  2. Moreland LW, Alten R, Van den Bosch F et al. (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-41g and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46:1470–9

    Article  PubMed  CAS  Google Scholar 

  3. Kremer JM, Westhovens R, Leon M et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA41g. N Engl J Med 349:1907–15

    Article  PubMed  CAS  Google Scholar 

  4. Genovese MC, Schiff M, Luggen M et al. (2008) Efficacy and safety of the selective costimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67: 547–54

    Article  PubMed  CAS  Google Scholar 

  5. Kremer JM, Genant HK, Moreland LW et al. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865–76

    Article  PubMed  CAS  Google Scholar 

  6. Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 37: 234–45

    Article  PubMed  CAS  Google Scholar 

  7. Pham T, Claudepierre P, Constantin A et al. (2009) Abatacept therapy and safety management. Joint Bone Spine 76 Suppl 1: S3–S55

    Article  PubMed  Google Scholar 

  8. European Medicines Agency. European Public Assessment Report. Orencia scientific discussion document 19 novembre 2009 http://www.emea.europa.eu/humandocs/pdfs/EPAR/orencia/H-701-enb6.pdf

  9. Sibilia J, Westhovens R (2007) Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 25: S46–56

    PubMed  CAS  Google Scholar 

  10. Smitten A, Simon T, Qi K et al. (2008) Hospitalized infections in the abatacept RA clinical development program: An epidemiological assessment with > 10,000 Person-years of exposure arthritis rheum 58: S786

    Google Scholar 

  11. Weinblatt M, Combe B, Covucci A et al. (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receivingbackgroundbiologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 54:2807–16

    Article  PubMed  CAS  Google Scholar 

  12. Miller KL, Sawitzke AD, Doane J (2008) Abatacept and serious respiratory infections in patients with previous lung disease. Clin Rheumatol 27:1569–71

    Article  PubMed  Google Scholar 

  13. Weinblatt M, Schiff M, Goldman A et al. (2007) Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66:228–34

    Article  PubMed  CAS  Google Scholar 

  14. Tay L, Leon F, Vratsanos G et al. (2007) Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 9: R38

    Article  PubMed  Google Scholar 

  15. Hodi FS, Mihm MC, Soiffer RJ et al. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A100: 4712–7

    Article  Google Scholar 

  16. Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175: 7746–54

    PubMed  CAS  Google Scholar 

  17. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116:1935–45

    Article  PubMed  CAS  Google Scholar 

  18. Wang X, Lin Q, Ma Z et al. (2005) Association of the A/G polymorphism at position 49 in exon 1 of CTLA-4 with the susceptibility to unexplained recurrent spontaneous abortion in the Chinese population. Am J Reprod Immunol 53:100–5

    Article  PubMed  CAS  Google Scholar 

  19. Mishra R, Singh V, Pritchard CH (2009) Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int

    Google Scholar 

  20. Emery P, Durez P, Dougados M et al. (2008) Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA. Ann Rheum Dis 67, Suppl II: 89

    Google Scholar 

  21. Ruperto N, Lovell DJ, Quartier P et al. (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet; 372:383–91

    Article  PubMed  CAS  Google Scholar 

  22. Vieira FI, Callado MR, Vieira WP (2009) Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatol Int

    Google Scholar 

  23. Olivieri I, D Angelo S, Mennillo GA et al. (2009) Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 68:151–2

    Article  PubMed  CAS  Google Scholar 

  24. Oracki SA, Tsantikos E, Quilici C et al. CTLA4Ig alters the course of autoimmune disease development in Lyn-/-mice. J Immunol 184:757–63

    Google Scholar 

  25. Schroder JO, Zeuner RA (2009) Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges. Curr Drug Discov Technol 6: 252–5

    Article  PubMed  Google Scholar 

  26. Kremer JM, Dougados M, Emery P et al. (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52: 2263–71

    Article  PubMed  CAS  Google Scholar 

  27. Genovese MC, Becker JC, Schiff M et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med;353:1114–23

    Article  PubMed  CAS  Google Scholar 

  28. Schiff M, Keiserman M, Codding C et al. (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–103

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Falgarone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Dumont-Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Saidenberg-Kermanac’h
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Falgarone, G., Dumont-Fischer, D., Saidenberg-Kermanac’h, N. (2011). L’abatacept dans la polyarthrite rhumatoïde. In: Biothèrapies en rhumatologie. Springer, Paris. https://doi.org/10.1007/978-2-8178-0124-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0124-7_6

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0123-0

  • Online ISBN: 978-2-8178-0124-7

Publish with us

Policies and ethics

Search

Navigation